If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-16. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
=== 2018–present: Business and continued television success === In December 2018, Kardashian became the brand ambassador of Burst Oral Care & performed corn test on the electric toothbrush. On June 14, 2019, Kylie Cosmetics launched their collaboration with Kardashian called Kylie Cosmetics x Koko Kollection. This marked their third collaboration, after previously launched special collection of lip products called Koko Kollection in 2016 and the second part in 2017. In August 2019, Kardashian announced she will become an executive producer for the new season of Twisted Sisters, an Investigation Discovery show, consisting of ten hour-long episodes following stories of sisters who turned on each other. In November 2019, Kardashian partnered with her sisters Kourtney and Kim to create three new perfumes (one for each sister) for Kim's brand KKW Fragrance. The collection introduces Pink Diamond (Khloé's fragrance), Yellow Diamond (Kourtney's fragrance) and pure Diamond (Kim's fragrance). Each scent is individually inspired by and unique to her, Kim, and Kourtney. In October 2020, it was announced she became the brand ambassador and co-owner of Kiwi collagen supplement company Dose & Co. In 2021, Kardashian and her family announced that their reality show, Keeping Up with the Kardashians, would be ending after twenty seasons and almost 15 years on air. In September 2021, Khloe Kardashian hosted a tournament for Candy Crush Saga, marking the game's first tournament. The tournament was held in-app from September 23 until October 7.
=== Tumor angiogenesis === AM contributes to tumor angiogenesis, given its capability to enhance smooth muscle and vascular endothelial cell development in addition to its role in ischemic revascularization. Similarly to other solid tumors, AM expression is increased by hypoxia, which has been regarded as an important regulator of tumor development with respect to the findings from animal and in vitro studies, although the translation application to human tumor development is constrained. AM is affiliated with endothelium-derived CC chemokine ligand 2 (CCL2) in the tumor microenvironment, employing genetic deletions and in vivo models to display functional associations. Tumor-derived AM stimulates angiogenesis and promotes tumor growth. Also, endothelial-derived CCL2 decreased AM-induced tumor growth. Deprivation of the AM receptor CALCRL or the G-protein Gs in endothelial cells diminishes both tumor and endothelial cell growth. Removing tumor cell CCR2 or endothelial CCL2 would undo this tumor growth decrease demonstrated in mice without endothelial CALCRL or Gs, displaying a reciprocal regulatory loop between AM and CCL2. AM contributes to cancer pathogenesis through heightened vascularization to equip tumors with nutrients and oxygen, more intense cell phenotypes, and increased cell proliferation. AM receptors (AM1 and AM2) have disparate effects in an array of cancers, with separate regulatory mechanisms and expression patterns.
== Non-medical hormonal interventions == In addition to the use of medication to produce tumor-suppressing endocrine alterations, destruction of endocrine organs through surgery or radiation therapy are also possible. Surgical castration, or removal of the testes in males and ovaries in females, have been widely used in the past to treat hormone-responsive prostate cancer and breast cancer respectively. However, these invasive methods have been widely supplanted by the use of GnRH agonists, and other forms of pharmacologic castration. There are still situations in which surgical castration may be beneficial such as in special cases for women with high risk BRCA mutations.
Only a few troops were directly registered and the practice was soon discontinued with new "mixed" groups being encouraged to join the WOSM member organization of their country of residence. In 1955, only two such groups were still active, a troop in Iraq that disbanded that year, and the first group to be so registered, the International Troop 1 in Yokohama. The only remaining directly registered Troop is the International Boy Scouts, Troop 1 located in Yokohama, Japan. Temporary recognition was extended to Scouts in displaced persons camps after World War II. In 1947, at WOSM's 11th conference the "Displaced Persons Division" of WOSM's bureau was established to register and support Scouts in displaced person camps in Austria, Northern Italy, and Germany. These Scouts did not receive the right of WOSM membership but gained recognition as Scouts under WOSM's bureau until they took up residence in a country that had a recognized national Scout organization, which they could join. The D.P. Division was closed on 30 June 1950.
Sources: en.wikipedia.org
== Experimental determination == Since the α-helix is defined by its hydrogen bonds and backbone conformation, the most detailed experimental evidence for α-helical structure comes from atomic-resolution X-ray crystallography such as the example shown at right. It is clear that all the backbone carbonyl oxygens point downward (toward the C-terminus) but splay out slightly, and the H-bonds are approximately parallel to the helix axis. Protein structures from NMR spectroscopy also show helices well, with characteristic observations of nuclear Overhauser effect (NOE) couplings between atoms on adjacent helical turns. In some cases, the individual hydrogen bonds can be observed directly as a small scalar coupling in NMR. There are several lower-resolution methods for assigning general helical structure. The NMR chemical shifts (in particular of the Cα, Cβ and C′) and residual dipolar couplings are often characteristic of helices. The far-UV (170–250 nm) circular dichroism spectrum of helices is also idiosyncratic, exhibiting a pronounced double minimum at around 208 and 222 nm. Infrared spectroscopy is rarely used, since the α-helical spectrum resembles that of a random coil (although these might be discerned by, e.g., hydrogen-deuterium exchange). Finally, cryo electron microscopy is now capable of discerning individual α-helices within a protein, although their assignment to residues is still an active area of research. Long homopolymers of amino acids often form helices if soluble.
=== Exercise === Exercise has been shown to improve insulin sensitivity in humans with metabolic syndrome. Increased exercise is therefore recommended in horses with EMS, assuming laminitis does not restrict activity levels. Current recommendations include 2–3 sessions a week, of 20–30 minutes of work, with gradual increase in duration and intensity.
The metabolism of propionyl-CoA occurs in the mitochondria and requires Vitamin B12 (as adenosylcobalamin) to make succinyl-CoA. When the conversion of propionyl-CoA to succinyl-CoA in the mitochondria fails due to Vitamin B12 deficiency, elevated blood levels of methylmalonic acid (MMA) occur. Thus, elevated blood levels of homocysteine and MMA may both be indicators of vitamin B12 deficiency. Adenosylcobalamin is needed as cofactor in methylmalonyl-CoA mutase—MUT enzyme. Processing of cholesterol and protein gives propionyl-CoA that is converted to methylmalonyl-CoA, which is used by MUT enzyme to make succinyl-CoA. Vitamin B12 is needed to prevent anemia, since making porphyrin and heme in mitochondria for producing hemoglobin in red blood cells depends on succinyl-CoA made by vitamin B12.
Sources: en.wikipedia.org
=== Neptunium-239 === Neptunium-239 has 146 neutrons and a half-life of 2.356 days. It is produced via β− decay of the short-lived uranium-239, and undergoes another β− decay to plutonium-239. This is the primary route for making plutonium, as 239U can be made by neutron capture in uranium-238. Uranium-237 and neptunium-239 are regarded as the leading hazardous radioisotopes in the first hour-to-week period following nuclear fallout from a nuclear detonation, with 239Np dominating "the spectrum for several days".
== External links == Overview of all the structural information available in the PDB for UniProt: P09958 (Human Furin) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P23188 (Mouse Furin) at the PDBe-KB.
=== Projects === Focke-Wulf 1000x1000x1000 – series of bomber designs, 1944. Focke-Wulf Project I – single-seat jet fighter, 1943. Focke-Wulf Project II Focke-Wulf Project III Focke-Wulf Project VII "Flitzer" – fighter project, 1944. Focke-Wulf Project VIII – turboprop powered fighter-bomber project, also designated Fw 281 Focke Rochen – 1950s VTOL fighter project Focke-Wulf Super Lorin – Ramjet-rocket combo powered fighter Focke-Wulf Fw 354 Triebflügel – tail-sitter VTOL interceptor design Focke-Wulf TO Project Focke-Wulf Volksjäger – rocket-powered interceptor fighter project Focke-Wulf VTOL Project
In nearly all human cultures, crying is associated with tears, active tear ducts and abrupt strong respiration, due to strong emotional impetuses. Triggers of crying can vary from sadness and grief to intense anger, happiness, fear, mirth, frustration, confusion, and any form of overwhelming stimuli. Emotional tears can also be triggered by social and personal experiences, like listening to music, reading social media content, sharing thoughts, and communicating. Crying is often associated with babies and children. The infants that are unable to vocally communicate have many alternating tones in their crying, attracting the attention of the caregiver and specifically their biological mothers. Blood-related mothers go through physiological changes upon exposure to the crying, with a deceleration in heart rate, followed by a quick acceleration, as well as understanding the vocalizations of the baby's crying. This is a mother-specific case, as the other caregivers, like biological father or adoptive parents, are not able to decode the sound. Some cultures consider crying to be undignified and infantile, casting aspersions on those who cry in public settings, excluding circumstances which concerns loss of a relative or a loved one. In most Western cultures, it is more socially acceptable for women and children to cry than men, reflecting masculine sex-role stereotypes. There is evidence for an interpersonal function of crying as tears express a need for help and foster willingness to help in an observer.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.